The ability of GSK2795039 (a pharmacological inhibitor of NOX2) and SOD to improve high glucose-induced endothelial dysfunction and attenuate ROS production in the WTD-GS (+) groups in the current experiment further confirms the previously established findings. This evidence concerns the gene SOD1 and endothelial dysfunction.